S. Michael Owens - Publications

Affiliations: 
Pharmacology and Toxicology University of Arkansas for Medical Sciences, United States 

73 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Hambuchen MD, Hendrickson HP, Owens SM. Chiral determination of 3,4-methylenedioxypyrovalerone enantiomers in rat serum. Analytical Methods : Advancing Methods and Applications. 9: 609-617. PMID 28286575 DOI: 10.1039/C6AY03176E  0.48
2016 Owens SM, Pollard GT, Howard JL, Fennell TR, Snyder RW, Carroll FI. Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats. Acs Chemical Neuroscience. PMID 27700049 DOI: 10.1021/acschemneuro.6b00249  0.32
2016 Reichard EE, Nanaware-Kharade N, Gonzalez GA, Thakkar S, Owens SM, Peterson EC. PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance. Pharmaceutical Research. PMID 27620175 DOI: 10.1007/s11095-016-2017-y  0.4
2016 Hambuchen MD, Rüedi-Bettschen D, Gunnell MG, Hendrickson H, Owens SM. Chronic Treatment of (+)-Methamphetamine-Induced Locomotor Effects in Rats Using One or a Combination of Two High Affinity Anti-Methamphetamine Monoclonal Antibodies. Human Vaccines & Immunotherapeutics. 0. PMID 27163775 DOI: 10.1080/21645515.2016.1179407  0.48
2016 Stevens MW, Gunnell MG, Tawney R, Owens SM. Optimization of a methamphetamine conjugate vaccine for antibody production in mice. International Immunopharmacology. 35: 137-141. PMID 27039212 DOI: 10.1016/j.intimp.2016.03.028  0.4
2015 Hambuchen MD, Carroll FI, Rüedi-Bettschen D, Hendrickson HP, Hennings LJ, Blough BE, Brieaddy LE, Pidaparthi RR, Owens SM. Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response. Journal of Medicinal Chemistry. 58: 4665-77. PMID 25973614 DOI: 10.1021/acs.jmedchem.5b00220  0.4
2014 Stevens MW, Henry RL, Owens SM, Schutz R, Gentry WB. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. Mabs. 6: 1649-56. PMID 25484042 DOI: 10.4161/19420862.2014.976431  0.4
2014 Laurenzana EM, Stevens MW, Frank JC, Hambuchen MD, Hendrickson HP, White SJ, Williams DK, Owens SM, Gentry WB. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development. Human Vaccines & Immunotherapeutics. 10: 2638-47. PMID 25483484 DOI: 10.4161/hv.29707  0.4
2014 Peterson EC, Hambuchen MD, Tawney RL, Gunnell MG, Cowell JL, Lay JO, Blough BE, Carroll FI, Owens SM. Simple radiometric method for accurately quantitating epitope densities of hapten-protein conjugates with sulfhydryl linkages. Bioconjugate Chemistry. 25: 2112-5. PMID 25426820 DOI: 10.1021/bc500456z  0.4
2014 Hambuchen MD, Rüedi-Bettschen D, Williams DK, Hendrickson H, Owens SM. Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period. Vaccine. 32: 6213-9. PMID 25252196 DOI: 10.1016/j.vaccine.2014.09.025  0.4
2014 White SJ, Hendrickson HP, Atchley WT, Laurenzana EM, Gentry WB, Williams DK, Owens SM. Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 1285-91. PMID 24839971 DOI: 10.1124/dmd.114.056879  0.4
2014 Stevens MW, Tawney RL, West CM, Kight AD, Henry RL, Owens SM, Gentry WB. Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use. Mabs. 6: 547-55. PMID 24492290 DOI: 10.4161/mabs.27620  0.4
2014 Peterson EC, Gentry WB, Owens SM. Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications. Advances in Pharmacology (San Diego, Calif.). 69: 107-27. PMID 24484976 DOI: 10.1016/B978-0-12-420118-7.00003-2  0.4
2013 Rüedi-Bettschen D, Wood SL, Gunnell MG, West CM, Pidaparthi RR, Carroll FI, Blough BE, Owens SM. Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food. Vaccine. 31: 4596-602. PMID 23906885 DOI: 10.1016/j.vaccine.2013.07.038  0.4
2011 Owens SM, Atchley WT, Hambuchen MD, Peterson EC, Gentry WB. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction. Cns & Neurological Disorders Drug Targets. 10: 892-8. PMID 22229314  0.4
2011 Hubbard JJ, Laurenzana EM, Williams DK, Gentry WB, Owens SM. Chronic anti-phencyclidine monoclonal antibody therapy decreases phencyclidine-induced in utero fetal mortality in pregnant rats. International Immunopharmacology. 11: 2181-7. PMID 22001428 DOI: 10.1016/j.intimp.2011.09.016  0.4
2011 Carroll FI, Blough BE, Pidaparthi RR, Abraham P, Gong PK, Deng L, Huang X, Gunnell M, Lay JO, Peterson EC, Owens SM. Synthesis of mercapto-(+)-methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines. Journal of Medicinal Chemistry. 54: 5221-8. PMID 21682289 DOI: 10.1021/jm2004943  0.4
2011 White S, Laurenzana E, Hendrickson H, Gentry WB, Owens SM. Gestation time-dependent pharmacokinetics of intravenous (+)-methamphetamine in rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 1718-26. PMID 21632964 DOI: 10.1124/dmd.111.039446  0.4
2011 Hubbard JJ, Laurenzana EM, Williams DK, Gentry WB, Owens SM. The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats. The Journal of Pharmacology and Experimental Therapeutics. 336: 414-22. PMID 20962030 DOI: 10.1124/jpet.110.175083  0.4
2010 Chimalakonda KC, Hailey C, Black R, Beekman A, Carlisle R, Lowman-Smith E, Singletary H, Owens SM, Hendrickson H. Development and validation of an LC-MS/MS method for determination of phencyclidine in human serum and its application to human drug abuse cases. Analytical Methods : Advancing Methods and Applications. 2: 1249-1254. PMID 20959870 DOI: 10.1039/C0AY00206B  0.4
2010 Gentry WB, Rüedi-Bettschen D, Owens SM. Anti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction. Clinical Pharmacology and Therapeutics. 88: 390-3. PMID 20668443 DOI: 10.1038/clpt.2010.155  0.4
2009 Carroll FI, Abraham P, Gong PK, Pidaparthi RR, Blough BE, Che Y, Hampton A, Gunnell M, Lay JO, Peterson EC, Owens SM. The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse. Journal of Medicinal Chemistry. 52: 7301-9. PMID 19877685 DOI: 10.1021/jm901134w  0.4
2009 Laurenzana EM, Hendrickson HP, Carpenter D, Peterson EC, Gentry WB, West M, Che Y, Carroll FI, Owens SM. Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats. Vaccine. 27: 7011-20. PMID 19800446 DOI: 10.1016/j.vaccine.2009.09.072  0.4
2009 Celikel R, Peterson EC, Owens SM, Varughese KI. Crystal structures of a therapeutic single chain antibody in complex with two drugs of abuse-Methamphetamine and 3,4-methylenedioxymethamphetamine. Protein Science : a Publication of the Protein Society. 18: 2336-45. PMID 19760665 DOI: 10.1002/pro.244  0.4
2009 Peterson EC, Owens SM. Designing immunotherapies to thwart drug abuse. Molecular Interventions. 9: 119-24. PMID 19592672 DOI: 10.1124/mi.9.3.5  0.4
2009 White SJ, Laurenzana EM, Gentry WB, Hendrickson HP, Williams DK, Ward KW, Owens SM. Vulnerability to (+)-methamphetamine effects and the relationship to drug disposition in pregnant rats during chronic infusion. Toxicological Sciences : An Official Journal of the Society of Toxicology. 111: 27-36. PMID 19520673 DOI: 10.1093/toxsci/kfp127  0.4
2009 Gentry WB, Rüedi-Bettschen D, Owens SM. Development of active and passive human vaccines to treat methamphetamine addiction. Human Vaccines. 5: 206-13. PMID 19276653 DOI: 10.4161/hv.5.4.7456  0.4
2008 Hendrickson HP, Hardwick WC, McMillan DE, Owens SM. Bioavailability of (+)-methamphetamine in the pigeon following an intramuscular dose. Pharmacology, Biochemistry, and Behavior. 90: 382-6. PMID 18455783 DOI: 10.1016/j.pbb.2008.03.012  0.4
2008 Peterson EC, Laurenzana EM, Atchley WT, Hendrickson HP, Owens SM. Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. The Journal of Pharmacology and Experimental Therapeutics. 325: 124-33. PMID 18192498 DOI: 10.1124/jpet.107.134395  0.4
2008 Lacy HM, Gunnell MG, Laurenzana EM, Owens SM. Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody. International Immunopharmacology. 8: 1-11. PMID 18068094 DOI: 10.1016/j.intimp.2007.09.020  0.4
2008 Naef L, Srivastava L, Gratton A, Hendrickson H, Owens SM, Walker CD. Maternal high fat diet during the perinatal period alters mesocorticolimbic dopamine in the adult rat offspring: reduction in the behavioral responses to repeated amphetamine administration. Psychopharmacology. 197: 83-94. PMID 18004547 DOI: 10.1007/s00213-007-1008-4  0.4
2007 Peterson EC, Gunnell M, Che Y, Goforth RL, Carroll FI, Henry R, Liu H, Owens SM. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. The Journal of Pharmacology and Experimental Therapeutics. 322: 30-9. PMID 17452421 DOI: 10.1124/jpet.106.117150  0.4
2007 Milesi-Hallé A, McMillan DE, Laurenzana EM, Byrnes-Blake KA, Owens SM. Sex differences in (+)-amphetamine- and (+)-methamphetamine-induced behavioral response in male and female Sprague-Dawley rats. Pharmacology, Biochemistry, and Behavior. 86: 140-9. PMID 17275894 DOI: 10.1016/j.pbb.2006.12.018  0.4
2006 Hendrickson H, Laurenzana E, Owens SM. Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection. The Aaps Journal. 8: E709-17. PMID 17233534 DOI: 10.1208/aapsj080480  0.4
2006 Peterson E, Owens SM, Henry RL. Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuse. The Aaps Journal. 8: E383-90. PMID 16796389 DOI: 10.1208/aapsj080243  0.4
2006 Gentry WB, Laurenzana EM, Williams DK, West JR, Berg RJ, Terlea T, Owens SM. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. International Immunopharmacology. 6: 968-77. PMID 16644483 DOI: 10.1016/j.intimp.2006.01.008  0.4
2006 Pitas G, Laurenzana EM, Williams DK, Owens SM, Gentry WB. Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 906-12. PMID 16507651 DOI: 10.1124/dmd.105.005934  0.4
2006 Daniels JR, Wessinger WD, Hardwick WC, Li M, Gunnell MG, Hall CJ, Owens SM, McMillan DE. Effects of anti-phencyclidine and anti-(+)-methamphetamine monoclonal antibodies alone and in combination on the discrimination of phencyclidine and (+)-methamphetamine by pigeons. Psychopharmacology. 185: 36-44. PMID 16479372 DOI: 10.1007/s00213-005-0299-6  0.4
2005 Byrnes-Blake KA, Laurenzana EM, Landes RD, Gentry WB, Owens SM. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. European Journal of Pharmacology. 521: 86-94. PMID 16182279 DOI: 10.1016/j.ejphar.2005.08.016  0.4
2005 Kosten T, Owens SM. Immunotherapy for the treatment of drug abuse. Pharmacology & Therapeutics. 108: 76-85. PMID 16023218 DOI: 10.1016/j.pharmthera.2005.06.009  0.4
2005 Milesi-Hallé A, Hendrickson HP, Laurenzana EM, Gentry WB, Owens SM. Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats. Toxicology and Applied Pharmacology. 209: 203-13. PMID 15916788 DOI: 10.1016/j.taap.2005.04.007  0.4
2005 Hendrickson HP, Whaley EC, Owens SM. A validated liquid chromatographic/tandem mass spectrometric method for the determination of phencyclidine in microliter samples of rat serum. Journal of Mass Spectrometry : Jms. 40: 19-24. PMID 15584009 DOI: 10.1002/jms.766  0.4
2004 Gentry WB, Ghafoor AU, Wessinger WD, Laurenzana EM, Hendrickson HP, Owens SM. (+)-Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration. Pharmacology, Biochemistry, and Behavior. 79: 751-60. PMID 15582684 DOI: 10.1016/j.pbb.2004.10.006  0.4
2004 Hendrickson HP, Milesi-Hallé A, Laurenzana EM, Owens SM. Development of a liquid chromatography-tandem mass spectrometric method for the determination of methamphetamine and amphetamine using small volumes of rat serum. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 806: 81-7. PMID 15171915 DOI: 10.1016/j.jchromb.2004.03.038  0.4
2004 McMillan DE, Hardwick WC, Li M, Gunnell MG, Carroll FI, Abraham P, Owens SM. Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. The Journal of Pharmacology and Experimental Therapeutics. 309: 1248-55. PMID 14993256 DOI: 10.1124/jpet.103.061762  0.4
2003 Laurenzana EM, Byrnes-Blake KA, Milesi-Hallé A, Gentry WB, Williams DK, Owens SM. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 31: 1320-6. PMID 14570763 DOI: 10.1124/dmd.31.11.1320  0.4
2003 Laurenzana EM, Gunnell MG, Gentry WB, Owens SM. Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody. The Journal of Pharmacology and Experimental Therapeutics. 306: 1092-8. PMID 12829731 DOI: 10.1124/jpet.103.053140  0.4
2003 Byrnes-Blake KA, Laurenzana EM, Carroll FI, Abraham P, Gentry WB, Landes RD, Owens SM. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. European Journal of Pharmacology. 461: 119-28. PMID 12586207 DOI: 10.1016/S0014-2999(03)01313-X  0.4
2002 McMillan DE, Hardwick WC, Li M, Owens SM. Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody. Behavioural Pharmacology. 13: 465-73. PMID 12394422  0.4
2001 Arora H, Owens SM, Gentry WB. Intravenous (+)-methamphetamine causes complex dose-dependent physiologic changes in awake rats. European Journal of Pharmacology. 426: 81-7. PMID 11525775  0.4
2001 Byrnes-Blake KA, Carroll FI, Abraham P, Owens SM. Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. International Immunopharmacology. 1: 329-38. PMID 11360933 DOI: 10.1016/S1567-5769(00)00019-9  0.4
2001 Kyosseva SV, Owens SM, Elbein AD, Karson CN. Differential and region-specific activation of mitogen-activated protein kinases following chronic administration of phencyclidine in rat brain Neuropsychopharmacology. 24: 267-277. PMID 11166517 DOI: 10.1016/S0893-133X(00)00180-9  0.4
2000 Proksch JW, Gentry WB, Owens SM. The effect of rate of drug administration on the extent and time course of phencyclidine distribution in rat brain, testis, and serum. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 28: 742-7. PMID 10859146  0.4
2000 Rivière GJ, Gentry WB, Owens SM. Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration Journal of Pharmacology and Experimental Therapeutics. 292: 1042-1047. PMID 10688621  0.4
2000 Proksch JW, Gentry WB, Owens SM. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. The Journal of Pharmacology and Experimental Therapeutics. 292: 831-7. PMID 10688594  0.4
1999 Rivière GJ, Byrnes KA, Gentry WB, Owens SM. Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. The Journal of Pharmacology and Experimental Therapeutics. 291: 1220-6. PMID 10565845  0.4
1999 Shelnutt SR, Gunnell M, Owens SM. Sexual dimorphism in phencyclidine in vitro metabolism and pharmacokinetics in rats Journal of Pharmacology and Experimental Therapeutics. 290: 1292-1298. PMID 10454506  0.4
1998 Proksch JW, Gentry WB, Owens SM. Pharmacokinetic mechanisms for obtaining high renal coelimination of phencyclidine and a monoclonal antiphencyclidine antigen-binding fragment of immunoglobulin G in the rat. The Journal of Pharmacology and Experimental Therapeutics. 287: 616-24. PMID 9808688  0.4
1998 Lim K, Owens SM, Arnold L, Sacchettini JC, Linthicum DS. Crystal structure of monoclonal 6B5 fab complexed with phencyclidine Journal of Biological Chemistry. 273: 28576-28582. PMID 9786848 DOI: 10.1074/jbc.273.44.28576  0.4
1998 Hardin JS, Wessinger WD, Proksch JW, Owens SM. Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs. The Journal of Pharmacology and Experimental Therapeutics. 285: 1113-22. PMID 9618414  0.4
1997 Owens SM. Antibodies as pharmacokinetic and metabolic modifiers of neurotoxicity Nida Research Monograph. 173: 259-272. PMID 9260192  0.4
1997 Laurenzana EM, Owens SM. Brain microsomal metabolism of phencyclidine in male and female rats Brain Research. 756: 256-265. PMID 9187340 DOI: 10.1016/S0006-8993(97)00203-5  0.4
1997 Laurenzana EM, Owens SM. Metabolism of phencyclidine by human liver microsomes Drug Metabolism and Disposition. 25: 557-563. PMID 9152594  0.4
1997 Shelnutt SR, Cornett LE, Owens SM. Phencyclidine continuous dosing produces a treatment time-dependent regulation of rat CYP2C11 function, protein expression and mRNA levels Journal of Pharmacology and Experimental Therapeutics. 281: 574-581. PMID 9103546  0.4
1997 Sharma U, Roberts ES, Kent UM, Owens SM, Hollenberg PF. Metabolic inactivation of cytochrome P4502B1 by phencyclidine: Immunochemical and radiochemical analyses of the protective effects of glutathione Drug Metabolism and Disposition. 25: 243-250. PMID 9029055  0.4
1996 Valentine JL, Owens SM. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats Journal of Pharmacology and Experimental Therapeutics. 278: 717-724. PMID 8768723  0.4
1996 Valentine JL, Mayersohn M, Wessinger WD, Arnold LW, Owens SM. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine- induced behavioral effects and ataxia in rats Journal of Pharmacology and Experimental Therapeutics. 278: 709-716. PMID 8768722  0.4
1996 Shelnutt SR, Badger TM, Owens SM. Phencyclidine metabolite irreversible binding in the rat: Gonadal steroid regulation and CYP2C11 Journal of Pharmacology and Experimental Therapeutics. 277: 292-298. PMID 8613933  0.4
1995 Laurenzana EM, Sorrels SL, Owens SM. Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human CYP2D6 Drug Metabolism and Disposition. 23: 271-278. PMID 7736924  0.4
1994 Valentine JL, Arnold LW, Owens SM. Anti-phencyclidine monoclonal Fab fragments markedly alter phencyclidine pharmacokinetics in rats Journal of Pharmacology and Experimental Therapeutics. 269: 1079-1085. PMID 8014850  0.4
1993 Owens SM, Gunnell M, Laurenzana EM, Valentine JL. Dose- and time-dependent changes in phencyclidine metabolite covalent binding in rats and the possible role of CYP2D1 Journal of Pharmacology and Experimental Therapeutics. 265: 1261-1266. PMID 8510006  0.4
1993 McClurkan MB, Valentine JL, Arnold L, Owens SM. Disposition of a monoclonal anti-phencyclidine Fab fragment of immunoglobulin G in rats Journal of Pharmacology and Experimental Therapeutics. 266: 1439-1445. PMID 8371148  0.4
1991 Wessinger WD, Owens SM. Phencyclidine dependence: The relationship of dose and serum concentrations to operant behavioral effects Journal of Pharmacology and Experimental Therapeutics. 258: 207-215. PMID 2072296  0.4
Show low-probability matches.